Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 Par Value
-
Shares outstanding
-
27,913,938
-
Total 13F shares
-
12,514,434
-
Share change
-
-520,044
-
Total reported value
-
$69,456,410
-
Put/Call ratio
-
189%
-
Price per share
-
$5.55
-
Number of holders
-
63
-
Value change
-
-$2,535,024
-
Number of buys
-
32
-
Number of sells
-
35
Institutional Holders of Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) as of Q2 2025
As of 30 Jun 2025,
Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,514,434 shares.
The largest 10 holders included
Soleus Capital Management, L.P., Velan Capital Investment Management LP, Carlyle Group Inc., QIMING U.S. VENTURES MANAGEMENT, LLC, MORGAN STANLEY, T. Rowe Price Investment Management, Inc., KINGDON CAPITAL MANAGEMENT, L.L.C., VANGUARD GROUP INC, Integral Health Asset Management, LLC, and Rock Springs Capital Management LP.
This page lists
63
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.